ExacTrac Dynamic delivers several new value drivers while still delivering key benefits like high performance, non-coplanar X-ray monitoring and submillimetric precision1. Combined, the new system expands utility beyond legacy stereotactic radiosurgery (SRS) capabilities into surface-guided radiation therapy opportunities.
Advanced technology development and integration: ExacTrac Dynamic addresses a full range of patient positioning and monitoring requirements through consolidation of internal tracking and surface guidance technologies, including a novel thermal surface camera.
New 4D thermal camera: Submillimetric accuracy1 is delivered with a single high-speed stereoscopic video camera system which incorporates 300,000 3-D surface points to externally monitor patient position and detect movement during treatment. Each of the surface points acquired by the ExacTrac Dynamic structured light system are matched to a corresponding heat signal generated by this new thermal camera, creating another dimension in which to track the patient’s position consistently, with great accuracy and very low latency.
New 4Pi frameless immobilization2: ExacTrac Dynamic simplifies frameless fixation with three moldable thermoplastic mask options designed with patient comfort in mind. A user-centric, clipless design provides accessory-free immobilization options for most linac couch tops.
ExacTrac Dynamic X-Ray monitoring: Deep integration with linear accelerators from both Elekta and Varian Medical Systems allow positioning and monitoring workflows to function seamlessly, including automatic patient loading, gantry or MU triggered imaging, and automated beam-hold with repositioning from outside the treatment room. These high-precision tracking and verification capabilities are critical requirements in the delivery of extremely effective and high doses in precision radiotherapy.
“The CE mark of ExacTrac Dynamic is a critical milestone toward future extra-cranial applications, including deep inspiration breath-hold and markerless tracking in the lung,” said Stefan Vilsmeier, president and CEO, Brainlab. “These trying and uncertain times re-emphasize the importance of preserving as much lung function as possible.”
1 data on file
2 FDA approval pending